(InSilico Medicine, Inc.) Insilico Medicine signed a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited. Juvenescence AI will develop the first compounds generated by Insilico's deep-learned drug discovery engines, which trained over structural, functional, and phenotypic data in order to predict the biological activity of compounds. Insilico's platforms incorporate new AI techniques such as Generative Adversarial Networks in order to generate novel compounds with desired pharmacokinetic and pharmacodynamic properties.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2uFYyrx
No comments:
Post a Comment